🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
NEX-I, Inc. (KOSDAQ:493410)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,275.00
0.00 (0.00%)
At close: Nov 17, 2026

NEX-I Company Description

NEX-I, Inc. develops, manufactures, and markets drugs and immunotherapies for cancer.

The company develops Phase 1 products, including NXI-101 and NXI-201, which are monoclonal antibodies, as well as various candidate products, such as NXI-S160, NXI-S301, and NXI-S172, which are antibody-drug conjugates, and NXI-401, a monoclonal antibody drug.

It also develops and provides NEXORA, a therapeutics platform; ONCOKINE, a factor associated with resistance to immuno-oncology therapies that suppresses tumor growth and induces immune cell activation in the tumor microenvironment; and SMRT, an immunotherapy in which resistant cancer cells alter the tumor microenvironment into an immunosuppressive state or acquire immune evasion mechanisms through the expression of specific cell surface proteins.

The company was founded in 2021 and is headquartered in Seoul, South Korea.

NEX-I, Inc.
CountrySouth Korea
Founded2021
CEOKyoung Wan Yoon

Contact Details

Address:
201 Songpa-daero
Seoul
South Korea
Phone82 2 6951 0412
Websitenex-i.co.kr

Stock Details

Ticker Symbol493410
ExchangeKOSDAQ
Stock TypeCommon Stock
Reporting CurrencyKRW
ISIN NumberKR7493410005

Key Executives

NamePosition
Kyoung Wan YoonChief Executive Officer
Jaemyoung ShimChief Financial Officer